MA53101A - Thiosulfate de sodium anhydre et formulations de celui-ci - Google Patents

Thiosulfate de sodium anhydre et formulations de celui-ci

Info

Publication number
MA53101A
MA53101A MA053101A MA53101A MA53101A MA 53101 A MA53101 A MA 53101A MA 053101 A MA053101 A MA 053101A MA 53101 A MA53101 A MA 53101A MA 53101 A MA53101 A MA 53101A
Authority
MA
Morocco
Prior art keywords
formulations
anhydrous sodium
sodium thiosulphate
thiosulphate
anhydrous
Prior art date
Application number
MA053101A
Other languages
English (en)
Inventor
Daniel Logan Kirschner
Christopher Mckinnon Lee
Thomas Claiborne Lovelace
Joseph Alexander Moore Iii
Original Assignee
Fennec Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69060534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53101(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fennec Pharmaceuticals Inc filed Critical Fennec Pharmaceuticals Inc
Publication of MA53101A publication Critical patent/MA53101A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00—Sulfur; Compounds thereof
    • C01B17/64—Thiosulfates; Dithionites; Polythionates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
MA053101A 2018-07-03 2019-07-01 Thiosulfate de sodium anhydre et formulations de celui-ci MA53101A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693502P 2018-07-03 2018-07-03
US201862693503P 2018-07-03 2018-07-03

Publications (1)

Publication Number Publication Date
MA53101A true MA53101A (fr) 2021-05-12

Family

ID=69060534

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053101A MA53101A (fr) 2018-07-03 2019-07-01 Thiosulfate de sodium anhydre et formulations de celui-ci
MA053102A MA53102A (fr) 2018-07-03 2019-07-01 Formulations de thiosulfate de sodium anhydre

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053102A MA53102A (fr) 2018-07-03 2019-07-01 Formulations de thiosulfate de sodium anhydre

Country Status (13)

Country Link
US (15) US10792363B2 (fr)
EP (2) EP3818010A4 (fr)
JP (2) JP7561325B2 (fr)
KR (2) KR20210027410A (fr)
CN (2) CN112805014A (fr)
AU (2) AU2019299217A1 (fr)
BR (2) BR112021000022A2 (fr)
CA (2) CA3103986A1 (fr)
IL (2) IL279857A (fr)
MA (2) MA53101A (fr)
MX (3) MX2020013733A (fr)
SG (2) SG11202013199UA (fr)
WO (2) WO2020009954A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
CN112805014A (zh) 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠的调配物
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
CN114848597A (zh) * 2022-07-11 2022-08-05 北京中科利华医药研究院有限公司 一种双室袋包装的硫代硫酸钠注射液和应用
CN116062708B (zh) * 2022-12-02 2024-09-17 东南大学 一种硫代硫酸钠的合成方法
US20240277758A1 (en) * 2022-12-28 2024-08-22 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Use of sodium thiosulfate for the treatment of sulfur mustard exposure

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191512599A (en) * 1915-09-02 1916-09-04 Thomas William Staine Hutchins Improvements in the Process for the Manufacture of Sodium Thiosulphate.
US2635980A (en) * 1950-02-11 1953-04-21 Wm S Merrell Co Stabilized sulfa drug
GB713559A (en) * 1951-12-14 1954-08-11 Kodak Ltd Improvements in the manufacture of the thiosulphates and seleno-sulphates of the alkali metals, calcium and ammonium
US2763531A (en) * 1952-11-29 1956-09-18 Eastman Kodak Co Manufacture of sodium thiosulphate from sodium sulfite and sulfur in presence of cationic surface active organic bromides
DE2851037C2 (de) * 1978-11-25 1980-10-02 Dr. Franz Koehler Chemie, 6146 Alsbach Verfahren zur Stabilisierung von für medizinische Zwecke bestimmten Natriumthiosulfat-Lösungen
US4778519A (en) 1987-02-24 1988-10-18 Batric Pesic Recovery of precious metals from a thiourea leach
BR0110403A (pt) * 2000-04-26 2004-02-25 Univ Oregon Health Sciences Administração de um composto quimioprotetor baseado em tiol
BR0306685A (pt) 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Composição farmacêutica contendo grelina
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
US20070059382A1 (en) 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
SG193216A1 (en) * 2008-08-18 2013-09-30 Amgen Fremont Inc Antibodies to ccr2
AU2010270605B2 (en) 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
EP2794582A1 (fr) 2011-12-23 2014-10-29 Mersana Therapeutics, Inc. Formulations pharmaceutiques pour conjugués de dérivé de fumagilline-phf
JP2015516407A (ja) 2012-05-10 2015-06-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 異所性石灰化の治療のためのチオ硫酸ナトリウム
JP5478680B2 (ja) 2012-08-23 2014-04-23 小林製薬株式会社 水溶性高分子増粘剤を含有する組成物の安定化剤
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CA2921847A1 (fr) 2013-09-16 2015-03-19 Basf Enzymes Llc Preparations enzymatiques de rupture controlee
CA2927393A1 (fr) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions et procedes pour toleriser des systemes cellulaires
WO2015085318A2 (fr) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Vaccins adaptatifs ciblés
BR112016024644A2 (pt) 2014-04-23 2017-10-10 Modernatx Inc vacinas de ácido nucleico
CN103922292A (zh) * 2014-04-29 2014-07-16 辽宁石化职业技术学院 硫代硫酸钠的制备方法
CN109562137A (zh) * 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
CN108473484B (zh) * 2015-10-01 2021-06-29 弗门尼舍公司 可用作trpm8调节剂的化合物
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
MX2018005100A (es) 2015-10-30 2019-05-16 Inception 3 Inc Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos.
US20170087199A1 (en) 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation
JP7033789B2 (ja) * 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
US20160376263A1 (en) 2016-07-26 2016-12-29 Senomyx, Inc. Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof
CN107963614A (zh) * 2016-10-20 2018-04-27 王亚玲 一种快速制备高纯度硫代硫酸钠晶体的方法
CN106379867A (zh) * 2016-10-21 2017-02-08 金川集团股份有限公司 一种生产五水硫代硫酸钠的方法
IL302827B2 (en) 2017-03-08 2024-10-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
SG11201911750RA (en) 2017-06-08 2020-01-30 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
US20210186943A1 (en) * 2018-04-25 2021-06-24 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
CN112805014A (zh) 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠的调配物
US10813947B1 (en) * 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Also Published As

Publication number Publication date
US20220378915A1 (en) 2022-12-01
MA53102A (fr) 2022-05-11
US20200023003A1 (en) 2020-01-23
US20230158145A1 (en) 2023-05-25
WO2020009954A1 (fr) 2020-01-09
US20240165237A1 (en) 2024-05-23
BR112021000022A2 (pt) 2021-03-30
MX2020013734A (es) 2021-05-27
US20230094886A1 (en) 2023-03-30
US11291728B2 (en) 2022-04-05
US11964018B2 (en) 2024-04-23
AU2019299217A1 (en) 2021-01-14
AU2019299216A1 (en) 2021-01-07
US20220160875A1 (en) 2022-05-26
US20230094842A1 (en) 2023-03-30
BR112021000021A2 (pt) 2021-03-30
US11510984B2 (en) 2022-11-29
EP3818010A4 (fr) 2022-08-17
IL279857A (en) 2021-03-01
SG11202013220SA (en) 2021-01-28
IL279856A (en) 2021-03-01
MX2020013733A (es) 2021-05-27
EP3817751A1 (fr) 2021-05-12
US20210015923A1 (en) 2021-01-21
WO2020009953A1 (fr) 2020-01-09
US20240042036A1 (en) 2024-02-08
US20240216511A1 (en) 2024-07-04
JP7561325B2 (ja) 2024-10-04
EP3818010A1 (fr) 2021-05-12
US20200009255A1 (en) 2020-01-09
SG11202013199UA (en) 2021-01-28
US20230201349A1 (en) 2023-06-29
KR20210027409A (ko) 2021-03-10
US10792363B2 (en) 2020-10-06
CN112805238A (zh) 2021-05-14
EP3817751A4 (fr) 2022-05-11
US20220323586A1 (en) 2022-10-13
US20230201351A1 (en) 2023-06-29
CA3103982A1 (fr) 2020-01-09
US11998604B2 (en) 2024-06-04
KR20210027410A (ko) 2021-03-10
JP2021530462A (ja) 2021-11-11
JP2021530420A (ja) 2021-11-11
CN112805014A (zh) 2021-05-14
MX2024003783A (es) 2024-04-10
US11992530B2 (en) 2024-05-28
US11617793B2 (en) 2023-04-04
CA3103986A1 (fr) 2020-01-09
US20230201350A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MA53101A (fr) Thiosulfate de sodium anhydre et formulations de celui-ci
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
GB201702613D0 (en) Oral cannabinoid formulations
DK3770160T3 (da) Kontrastmidler baseret på gadolinium-indeholdende pcta
IL277943A (en) Stable formulations of anti-CD79B immunoconjugate
DK3810241T3 (da) Intuberingsindretninger
DK3638251T3 (da) Bisphosphocin gel formuleringer og brug deraf
JP1638163S (ja) 内視鏡用プロセッサ
DK3651736T3 (da) Langtidsvirkende formuleringer
ES2898975R1 (es) Endoscopio
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
DK3886820T3 (da) Kapselformuleringer
ZA202000490B (en) Novel secnidazole soft gelatin capsule formulations and uses thereof
CL2018001505S1 (es) Protector intimo femenino
MA51009A (fr) Composition de soins buccaux
ES2982098T3 (es) Endoscopio
DK3911298T3 (da) Formuleringer
DK3736810T3 (da) Hovedskal
DE112019004134A5 (de) Tampon
ES2982268T3 (es) Producción de bicarbonato de sodio
DK3664800T3 (da) Terapeutiske formuleringer omfattende COX-2-inhibitor og anvendelse deraf
DK3520622T3 (da) Sukkerfri hård dragé
GB2608959B (en) Animal enclosure coupling
MA51199A (fr) Agents d'imagerie
JP1742682S (ja) シェイプドパウチ